AzTrials
AzTrials

Acute Respiratory Distress SyndromeDeVENTNCT04115709

Decision Support System to Evaluate VENTilation in ARDS

A study testing Beacon Caresystem device with advice and Beacon Caresystem device without advice activated in people with Acute Respiratory Distress Syndrome, run by Imperial College London at 3 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients with Acute Respiratory Distress Syndrome (ARDS) residing in the intensive care unit (ICU) often require support for their breathing from a mechanical ventilator to provide adequate gas exchange, and although it is life-saving in this setting, it is also known to contribute to the morbidity and mortality in… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Acute Respiratory Distress Syndrome
What is being tested?
Beacon Caresystem device with advice and Beacon Caresystem device without advice activated
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
95 participants
Where
3 sitesin 3 countries
Study dates
19 Mar 2020to 30 Aug 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Invasive mechanical ventilation.
  • Within 1 week of a known clinical insult or new or worsening respiratory symptoms
  • Chest radiograph with bilateral infiltrates consistent with evidence of pulmonary oedema but not fully explained by cardiac failure.
  • Hypoxaemia as defined by PaO2/FiO2 of ≤ 300mmHg (or ≤ 40kPa) (pre-ECMO PaO2/FiO2 will be used should patient be placed on extracorporeal support).
  • 18 years or older
  • Able to consent
  • Have mental capacity

Who cannot join

  • Age < 18 years old.
  • The absence of an arterial catheter for blood sampling at study start.
  • Consent declined.
  • Over 7 days of mechanical ventilation.
  • Treatment withdrawal imminent within 24 hours.
  • DNAR (Do Not Attempt Resuscitation) order in place
Show all 17Show fewer
  • Severe chronic respiratory disease requiring domiciliary ventilation (except for sleep disordered breathing)
  • Veno-Arterial ECMO
  • Healthy Volunteer Sample collection:
  • Blood borne viruses: HIV, Hep B, Hep C
  • Blood taken in the last 7 days
  • Under doctor for investigation
  • Haematological disease
  • Currently suffers from infection
  • Needle phobia
  • Problems with veins / vessels
  • Refusal

Trial locations and contacts

3 sites in 3 countries.

3 sites in 3 countries

Austria1 site
  • Medical University of Vienna

    Vienna, Waehringer Guertel, A-1090

Other trials in Austria

France1 site
  • Université Clermont Auvergne

    Clermont-Ferrand, 63003

Other trials in France

United Kingdom1 site
  • Imperial College London, Royal Brompton Hospital campus

    London, SW3 6NP

Other trials in United Kingdom

About this study

Official title: Decision Support System to Evaluate VENTilation in ARDS (DeVENT)

Patients with Acute Respiratory Distress Syndrome (ARDS) residing in the intensive care unit (ICU) often require support for their breathing from a mechanical ventilator to provide adequate gas exchange, and although it is life-saving in this setting, it is also known to contribute to the morbidity and mortality in the condition.

Mechanical ventilation delivers a volume and pressure of gas for each breath and can vary oxygen levels. Selecting the correct oxygen, pressure and volume levels is important, as incorrect levels can harm the patient, and result in an increased time connected to the ventilator.

Read more

Recently, a system has been developed (the Beacon Caresystem) which advises the healthcare practitioner by the bedside as to how to best set the ventilator. This system is based on mathematics which describes the patients disease and may therefore provide ventilator settings which better suit the individual.

The purpose of this study is to compare mechanical ventilation in ARDS patients following advice from the Beacon Caresystem to that of standard care to investigate whether the use of the system results in improved ventilation in all severities and phases of ARDS and thus reducing morbidity in ARDS. The investigators plan to recruit 110 patients (50 in the UK and 30 in each of the other 2 sites). The study also aims to examine the biological and physiological factors that determine the worsening of ARDS and the processes involved in recovery from ARDS with the aim to develop new therapies to help detect the condition and improve recovery.

The investigators will utilise all raw data will be collected from the Beacon Caresystem to physiologically characterise the progression and resolution phases of ARDS.

Additionally blood and Urine samples will be taken from healthy volunteers (100 in total) as a control comparison group for the biological analyses carried out in the DeVENT study.

Read the detailed description

The study is a randomised control trial, comparing the effects of mechanical ventilation in ARDS provided as standard care, with mechanical ventilation set according to the advice of the Beacon Care system. The study will compare if the use of the system results in a better application of PEEP and driving pressure across all severities and phases of ARDS.

The broad timeframe for the study is as follows. The study will be conducted at three sites. Two of these sites are outside the UK, one in France and one in Italy.

The systems will be delivered and installed starting September/October 2019 in the UK site, followed by France and Austria in November 2019. A one month period of training will then follow where all doctors and nurses involved in using the system will be trained. During this period none of the systems advice will be applied. This training will be supported by study partners, and nurses trained as super users of the system, by Mermaid Care A/S, the company producing the system, and by project investigators who have previously conducted studies using the system.

Patient inclusion and data collection will be performed at in the UK sites over a 15 month period from start October 2019 to January 2020. In both European sites, inclusion and data collection will be performed over a 12 month period from start January 2020 to December 2020. Final data analysis and report writing will be performed by March 2021.

For all study sites, all adult patients diagnosed with ARDS in the cardio-thoracic intensive care unit (ICU) undergoing mechanical ventilation will be considered to see if they are eligible for the study.

Patients will only be considered eligible if they are Within 7 days of an acute and potentially reversible episode of acute respiratory failure, their chest radiograph with bilateral infiltrates is consistent with evidence of pulmonary oedema but not fully explained by cardiac failure and they present with hypoxaemia. In addition, patients are not considered eligible due to being aged under 18, not having an arterial catheter for blood sampling at study start, consent declined, over 7 days of mechanical ventilation, treatment withdrawal imminent within 24 hours, Do Not Attempt Resuscitation order in place and for having a severe chronic respiratory disease requiring domiciliary ventilatioin. For each patient, if identified as eligible, advice to participate in the study will be sought.

Critically ill patients are and often unconscious and may not be able to grant consent. Therefore, the Patient Informed Sheet (PIS) and Consent Form will be requested from a third party acting as a consultee; in most cases this person will be a Personal Consultee, who is someone who knows the person lacking capacity and is able to advise the researcher about that person's wishes and feelings in relation to the project and whether they should join the research. This person must be interested in the welfare of the patient in a personal capacity, not in a professional capacity or for remuneration and will mostly likely be family member, carer or friend, etc. Where the personal consultee is not available on site, the researcher may contact the personal consultee by telephone and seek verbal advice. The verbal agreement will be recorded in the telephone consultee declaration form. The telephone consultee declaration form will be signed by a second member of staff who has witnessed the telephone advice. A copy of the PIS will be emailed to the personal consultee.

Where no Personal Consultee is available, the researcher will nominate a professional person to assist in determining the participation of a person who lacks capacity. A Nominated Professional Consultee is someone who will be appointed by the researcher to advise the researcher about the person's (who lacks capacity) wishes and feelings in relation to the project and whether they should join the research. An independent clinician not treating the patient will be asked to be the nominated consultee. A patient information sheet will be distributed immediately following the patient being identified as eligible for the study.

The study investigators will ask the patient if they can use their existing hospital records. Without their consent, no additional information about the patient will be collected for the purposes of the study. However, to maintain integrity of the randomised trial, all information collected up to that time will still be used and analysed as part of the study.

If consent is obtained and the patient is still eligible, then they will be randomly allocated to one of two groups. This random allocation will be performed according to the randomisation template with random block allocation.

If the patient is allocated to the standard care group then all care will be according to usual practice. If the patient is allocated to the Beacon group, mechanical ventilation will be set with advice from the system. In either case, the study ends for the individual patient either with successful transfer of the patient to another department, or patient death. All other care will be according to usual practice.

110 patients will be included in the study, with 55 patients in each of the groups. 55 patients per group will allow to detect a difference of 3cmH2O in driving pressure between the groups with 90% power and a two sided alpha of 0.05 assuming a control group driving pressure of 15 cmH2O with a standard deviation of 2.5 cmH2O and including a 40% dropout. The investigators have used data from the MIMIC dataset (as published in Serpo Neto et al) for the estimation of the driving pressure. In view of the longitudinal analysis, loss to follow up has taken account of an average mortality of 34% and a 6% drop out.

Being tested
Beacon Caresystem device with advice, Beacon Caresystem device without advice activated
Keywords
Acute Respiratory Distress Syndrome, Intensive Care, Device, Beacon Caresystem©, Ventilation
Medical subject headings
Respiratory Distress Syndrome, Respiratory Aspiration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Beacon Caresystem device with adviceDevice

    Beacon Caresystem device provides ventilator settings advice to Doctors

  • Beacon Caresystem device without advice activatedDevice

    Beacon Caresystem device does not give ventilator settings advice

Study groups in NCT04115709
Study groupRoleWhat they receive
Intervention: Device attached with advice activatedExperimentalBeacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
Receives: Device: Beacon Caresystem device with advice
Control: standard care with device attached without adviceActive comparatorBeacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
Receives: Device: Beacon Caresystem device without advice activated

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average Driving pressure delivery by the mechanical ventilator

    To assess the average driving pressure delivered by the mechanical ventilator over the period of time when ARDS ventilation management is advised by the Beacon Caresystem as compared to standard care.

    Measured: 18 months

Secondary outcomes (37)
  1. Daily Average physiological status - oxygenation (SpO2)

    • Daily average physiological status defined as daily averages of measured values of oxygenation (SpO2)

    Measured: 18 months

  2. Daily Average physiological status - end-tidal CO2 fraction (FE'CO2)

    • Daily average physiological status defined as daily averages of measured values end-tidal CO2 fraction (FE'CO2)

    Measured: 18 months

  3. Daily Average physiological status - metabolism (VO2, VCO2)

    • Daily average physiological status defined as daily averages of measured values of metabolism (VO2, VCO2)

    Measured: 18 months

  4. Daily Average physiological status - ventilation (respiratory rate)

    • Daily average physiological status defined as daily averages of measured values of ventilation (respiratory rate)

    Measured: 18 months

  5. Daily Average physiological status - ventilation (tidal volume)

    • Daily average physiological status defined as daily averages of measured values of ventilation (tidal volume)

    Measured: 18 months

  6. Daily Average physiological status - ventilation (anatomical dead space)

    • Daily average physiological status defined as daily averages of measured values of ventilation (anatomical dead space)

    Measured: 18 months

  7. Daily Average physiological status - pulmonary mechanisms (mean airway pressure)

    • Daily average physiological status defined as daily averages of measured values of pulmonary mechanisms (mean airway pressure)

    Measured: 18 months

  8. Daily Average physiological status

    • Daily average physiological status defined as daily averages of measured values of pulmonary mechanisms (respiratory system compilance)

    Measured: 18 months

  9. Daily Average physiological status

    • Daily average physiological status defined as daily averages of measured values of ventilator settings

    Measured: 18 months

  10. Daily Average physiological status - PaO2/FiO2

    • Daily average physiological status defined as daily averages of measured values of PaO2/FiO2

    Measured: 18 months

  11. Daily Average physiological status - shunt fraction

    • Daily average physiological status defined as daily averages of measured values of shunt fraction

    Measured: 18 months

  12. Daily Average physiological status - end-expiratory lung volume

    • Daily average physiological status defined as daily averages of measured values of end-expiratory lung volume over time as continuously measured by the Beacon system

    Measured: 18 months

  13. Daily average calculated delivered pressure over time

    • Daily average calculated delivered pressure over time, for periods of spontaneous breathing.

    Measured: 18 months

  14. Daily average calculated mechanical power over time

    • Daily average calculated mechanical power over time

    Measured: 18 months

  15. Daily average calculated oxygenation index over time

    • Daily average calculated oxygenation index over time

    Measured: 18 months

  16. Daily average ventilatory ratio over time

    • Daily average ventilatory ratio over time

    Measured: 18 months

  17. Incidence and duration of proning events and pre- and post- respiratory physiology

    • Incidence and duration of proning events and pre- and post- respiratory physiology

    Measured: 18 months

  18. Ventilator free days at 28 days.

    • Ventilator free days at 28 days.

    Measured: 28 days

  19. Composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors

    • Composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors

    Measured: 28 days

  20. Time from control mode to support mode

    • Time from control mode to support mode

    Measured: 18 months

  21. Proportion of breaths dysyncronous with the ventilator

    • Proportion of breaths dysyncronous with the ventilator

    Measured: 18 months

  22. Number of changes in ventilator settings per day

    • Number of changes in ventilator settings per day

    Measured: 18 months

  23. Percentage of time in control mode ventilation

    • % of time in control mode ventilation

    Measured: 18 months

  24. Percentage of time in support mode ventilation

    • % of time in support mode ventilation

    Measured: 18 months

  25. Total duration of mechanical ventilation

    • Total duration of mechanical ventilation

    Measured: 18 months

  26. Changes in tidal volume over time

    • Changes in tidal volume over time

    Measured: 18 months

  27. Changes in Positive End Expiratory Pressure (PEEP) setting over time

    • Changes in Positive End Expiratory Pressure (PEEP) setting over time

    Measured: 18 months

  28. Daily and cumulative fluid balance.

    • Daily and cumulative fluid balance.

    Measured: 18 months

  29. Timing, incidence and duration of ECMO

    • Timing, incidence and duration of ECMO

    Measured: 18 months

  30. Timing, incidence and duration of neuromuscular blockade

    • Timing, incidence and duration of neuromuscular blockade

    Measured: 18 months

  31. Mortality at 28 days

    Mortality at 28 days

    Measured: 28 days

  32. Mortality at 6 months

    Mortality at 6 months

    Measured: 6 months

  33. Mortality at 1 year

    Mortality at 1 year

    Measured: 1 year

  34. Organ failure assessment (SOFA) score and/or delta SOFA

    • Organ failure free days in the first 28 days, assessed using the sequential organ failure assessment (SOFA) score and/or delta SOFA

    Measured: 28 days

  35. Number of patients with ventilation related complications

    Number of patients with ventilation related complications e.g. pneumothorax and/or pneumomediastinum

    Measured: 18 months

  36. Device malfunction event rate

    • Device malfunction event rate

    Measured: 18 months

  37. Number of times the advice from the Beacon system is followed

    • Number of times the advice from the Beacon system is followed

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2019
  2. Study start19 Mar 2020
  3. Primary completion30 Mar 2021
  4. Study completion30 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
95 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04115709
Sponsor's protocol ID
19IC5421
Acronym
DeVENT
Status last verified
Sep 2021
First submitted
2 Sep 2019
Last updated
16 Sep 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Patel BV, Mumby S, Johnson N, Handslip R, Patel S, Lee T, Andersen MS, Falaschetti E, Adcock IM, McAuley DF, Takata M, Staudinger T, Karbing DS, Jabaudon M, Schellongowski P, Rees SE; DeVENT Study Group. A randomized control trial evaluating the advice of a physiological-model/digital twin-based decision support system on mechanical ventilation in patients with acute respiratory distress syndrome. Front Med (Lausanne). 2024 Oct 30;11:1473629. doi: 10.3389/fmed.2024.1473629. eCollection 2024.

    PubMed 39540041
  • Patel B, Mumby S, Johnson N, Falaschetti E, Hansen J, Adcock I, McAuley D, Takata M, Karbing DS, Jabaudon M, Schellengowski P, Rees SE; DeVENT study group. Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol. Trials. 2022 Jan 17;23(1):47. doi: 10.1186/s13063-021-05967-2.

    PubMed 35039050

Questions about this trial

What is this clinical trial studying?

A study testing Beacon Caresystem device with advice and Beacon Caresystem device without advice activated in people with Acute Respiratory Distress Syndrome, run by Imperial College London at 3 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Austria, France, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average Driving pressure delivery by the mechanical ventilator (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04115709, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
DeVENT Clinical Trial NCT04115709 | AzTrials